Pfizer to Sell £2 Billion Stake in Consumer Health Giant Haleon

The sale reduces Pfizer's ownership from 32% to 24%, marking a significant shift in its investment strategy.

Pfizer Inc. announces plans to sell approximately £2 billion ($2.5 billion) of shares in Haleon Plc, reducing its stake from 32% to about 24%.
Haleon, known for products like Sensodyne toothpaste and Advil painkillers, was formed by merging GSK and Pfizer's consumer health units.
The share sale is part of Pfizer's broader strategy to focus on its core pharmaceutical innovations and reduce debt.
Haleon to repurchase about £315 million of its shares from Pfizer, as part of the deal.
The sale and repurchase announcement has led to a slight decrease in Haleon's share price in early trading.